Gradient Bioconvergence (CEO Jin-Geun Lee) announced that it will participate in 'BIO-EUROPE Spring 2025' held in Milan, Italy from the 17th to the 19th. At this exhibition, it will operate individual booths to introduce patient-derived organoid (PDO) banking, induced pluripotent stem cell (iPSC)-based brain organoids, and new target discovery platforms, and seek opportunities for cooperation with global pharmaceutical and bio companies.
First, Gradient Bioconvergence plans to introduce a PDO-based drug efficacy evaluation platform and further expand related businesses through collaboration with overseas contract research organizations (CROs). Recently, organoid-based drug efficacy evaluation has been gaining attention as a promising approach to increasing clinical success rates in the new drug development process, and the company has the competitive edge of possessing approximately 800 types of PDO banking, the largest in the industry, as well as a collaboration portfolio with numerous domestic and foreign companies.
In particular, the recently established co-culture model of iPSC-derived microglia and brain organoids is a model capable of simulating the neuroinflammatory response that occurs in most degenerative brain diseases. By utilizing this model, it is expected that the interest of visiting companies will be high as it will be possible to conduct efficacy evaluations of Alzheimer's, Parkinson's, and Huntington's disease treatments in a more realistic environment.
Gradient Bioconvergence's organoids are linked to the patient's clinical information and genomic information (NGS), so they can be used not only for more precise efficacy evaluation during the new drug development process, but also for discovering biomarkers and new targets. The target discovery platform, which uses its own AI patented technology, quickly and precisely analyzes massive PDO data and increases the accuracy of new target discovery. Based on this, it will support new drug R&D companies to derive more reliable targets, and verified internal target tasks will be developed in cooperation with partner pharmaceutical companies to speed up drug development.
“Following a contract from a major pharmaceutical company last year to evaluate the efficacy of targeted anticancer drugs, we recently signed a contract with another major domestic pharmaceutical company for the development of next-generation anticancer drugs,” said Jin-Geun Lee, CEO of Gradient Bioconvergence. “This contract, in particular, is largely a proof-of-concept (PoC) study, so we expect it to lead to larger follow-up contracts in the future.”
CEO Lee Jin-geun continued, “As the movement to utilize the organoid platform for new drug development is growing, we will emphasize our technological differentiation at Bio Europe Spring 2025 and expand cooperation with the global pharmaceutical and bio industries.”
- See more related articles
You must be logged in to post a comment.